Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The Trump administration is set to announce a new wave of drug pricing agreements with Bayer, Takeda, CSL, and several mid-size biotechs. This builds on earlier deals with 17 major drugmakers — including Pfizer, Eli Lilly, and Amgen — aimed at bringing U.S. drug prices in line with other developed nations. The broader initiative is projected to save up to $64.3 billion in federal and state spending over the next decade.
The Trump administration is expanding its drug pricing push, with a new round of agreements expected to be announced involving Bayer, Takeda, CSL, and several mid-size biotechs. The deals follow earlier agreements struck with 17 of the world's largest pharmaceutical companies — including Pfizer, Eli Lilly, and Amgen — under a "most-favored-nation" pricing framework that ties U.S. drug prices to what patients pay in other developed countries.
Smaller and mid-sized drugmakers had been notably slow to join the effort. A Reuters report from June found that only Japan's Astellas had confirmed applying for the Medicaid pricing program, with some executives citing limited financial incentive. The new announcements signal a broader expansion of the initiative ahead of this year's midterm elections.
By the Numbers:
Why it matters: Drug affordability remains a top concern for American patients and policymakers alike. While the projected savings are speculative and Medicaid already receives steep discounts under existing law, the administration's push to rope in mid-size pharma signals a more sweeping effort to reshape how drugs are priced in the U.S.
